New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
05:34 EDTTKPPYTechnip upgraded to Neutral from Reduce at Nomura
News For TKPPY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
05:12 EDTTKPPYTechnip awarded subsea contract for South Santa Cruz and, Barataria fields
Technip has been awarded a lump sum contract by Deep Gulf Energy III for the development of the South Santa Cruz and Barataria fields. These ultra-deepwater fields are located in Mississippi Canyon, offshore New Orleans, in the Gulf of Mexico, in approximately 2,000 meters of water depth. Covering all aspects of the field development from engineering to design, manufacturing and installation, this new award highlights Technip's unique vertical integration in the subsea business environment. Technip's operating center in Houston, Texas, will manage the overall project. The flowline system will be fabricated at the Group's spoolbase in Mobile, Alabama, USA. The offshore installation is expected to be performed in the second half of 2016 by Technip's vessel the Deep Blue, the Group's flagship vessel for deepwater pipelay.
February 3, 2016
09:32 EDTTKPPYHarris & Harris, Mersana Therapeutics, expand partnership with Technip
Harris & Harris notes the announcement by its portfolio company, Mersana Therapeutics, that Mersana and Takeda Pharmaceutical have entered a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer antibody-drug conjugate, or ADC, platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Mersana will receive an upfront payment of $40M and an additional payment of $20M upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20M in equity in future rounds of Mersana financing.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use